View Older Stories View More Recent Stories

Jun 27, 2022 09:00AM Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
Jun 24, 2022 08:00AM Gilead Sciences (GILD) Announces Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Jun 24, 2022 08:00AM Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Jun 23, 2022 08:31AM Gilead Sciences (GILD) Announces Treatment With Hepcludex Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
Jun 23, 2022 08:30AM Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
Jun 21, 2022 09:00AM Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
Jun 6, 2022 09:00AM Gilead Sciences (GILD) Reports Final Data From Phase 3 ASCENT Study Showing Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
Jun 6, 2022 09:00AM Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
Jun 6, 2022 05:51AM Gilead Sciences (GILD) Reports Tecartus Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up
Jun 4, 2022 04:00PM Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell
Jun 4, 2022 01:38PM Gilead Sciences (GILD) Reports Trodelvy Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 4, 2022 09:00AM Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphom
Jun 4, 2022 08:00AM Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients
Jun 3, 2022 04:00PM Gilead Sciences's (GILD) Kite Announces Yescarta CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
Jun 3, 2022 04:00PM Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
Jun 2, 2022 09:00AM Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
May 19, 2022 01:30PM Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
May 17, 2022 04:30PM Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
May 16, 2022 04:10PM Gilead Sciences (GILD) Announces FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
May 16, 2022 04:10PM FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
May 16, 2022 07:30AM Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors
May 2, 2022 08:32AM Gilead Sciences (GILD) and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
May 2, 2022 08:30AM Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
Apr 26, 2022 06:13PM Gilead Sciences to Present at Upcoming Investor Conferences
Apr 25, 2022 02:29PM Gilead Sciences (GILD) Announces Veklury (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
Apr 25, 2022 02:29PM Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
Apr 25, 2022 05:24AM Gilead Sciences (GILD) Reports New Findings Confirming Veklury Activity in Treating COVID-19
Apr 24, 2022 06:05PM Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
Apr 19, 2022 08:07AM Gilead Sciences' (GILD) Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
Apr 19, 2022 08:00AM Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
Apr 14, 2022 04:05PM Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
Apr 11, 2022 04:07PM Gilead Sciences (GILD) Announces FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
Apr 11, 2022 04:07PM FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
Apr 1, 2022 06:01PM Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
Mar 28, 2022 11:00AM Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
Mar 7, 2022 08:31AM Gilead Sciences (GILD) Reports Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival
Mar 7, 2022 08:30AM Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer
Mar 1, 2022 08:33AM Gilead Sciences (GILD) Receives CRL from FDA for Investigational Lenacapavir Due to Vial Compatability Issues
Mar 1, 2022 08:30AM Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues
Feb 16, 2022 01:58PM Gilead Sciences (GILD) Announces New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
Feb 16, 2022 01:55PM New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
Feb 11, 2022 05:16PM Gilead Sciences (GILD) to Present New Phase 2/3 Interim Data of Veklury in Pediatric Patients With COVID-19 Presented at CROI 2022
Feb 11, 2022 05:15PM Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022
Feb 11, 2022 05:00PM Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
Feb 11, 2022 08:01AM Gilead Sciences (GILD) Announces Veklury Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
Feb 11, 2022 08:01AM Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
Feb 8, 2022 08:31AM Gilead Sciences (GILD) to Present Latest Antiviral Research and Development Data at CROI
Feb 8, 2022 08:30AM Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
Feb 3, 2022 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Feb 1, 2022 04:10PM Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
View More Recent Stories View Older Stories